ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in serious adverse eventso compared with placebo (moderate certainty).
ChAdOx1 – AstraZeneca + University of Oxford probably leads to higher local reactogenicity eventsi compared with placebo (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… probably leads to lower systemic reactogenicity eventsb compared with chAdOx1 – University of Oxford (moderate certainty).
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… showed no clear difference in any adverse evente compared with chAdOx1 – University of Oxford (low certainty).
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… showed no clear difference in serious adverse eventsg compared with chAdOx1 – University of Oxford (low certainty).
BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in all‐cause mortalityg compared with placebo (low certainty).
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… showed no clear difference in local reactogenicity eventsb compared with chAdOx1 – University of Oxford (low certainty).
The review found no eligible studies for this question.
AD26.COV2.S – Janssen Pharmaceutical Companies leads to lower all‐cause mortalityb compared with placebo (high certainty).
AD26.COV2.S – Janssen Pharmaceutical Companies showed no clear difference in serious adverse eventsb compared with placebo (moderate certainty).
AD26.COV2.S – Janssen Pharmaceutical Companies leads to higher systemic reactogenicity eventse compared with placebo (high certainty).
The review found no eligible studies for this question.